This is a retrospective analysis of 188 children who underwent total body irradiation (TBI) in one or two fractions before bone marrow transplantation (BMT) for a hematological disorder. While 139 children had eye shielding during TBI to decrease cataract formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of relapse in the eyes or in the CNS after shielding of the eyes. The probability and severity of cataract formation with and without shielding were also evaluated. None of the 49 children without shielding had a relapse in their eyes or in the CNS after BMT. Of the children with shielding, none had a relapse in the eyes but two of the 139 (1.4%) had a CNS relapse. The incidence of cataracts without shielding was 90% (19 of 21 evaluable patients), while with shielding it was 31% (20 of 64). Severe cataracts were present in eight of 21 (38%) patients without and two of 64 (3%) patients with shielding. The probability of staying cataract free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a cataract without shielding vs shielding was three (95% CI ¼ 1.5; 5.9). It appears that the incidence of relapse in the eyes and CNS is not increased when the eyes are shielded during TBI. Shielding increased the latency time of cataract formation and decreased the severity of cataracts. Bone Marrow Transplantation (2003) 31, 1151-1156. doi:10.1038/sj.bmt.1704076 Keywords: TBI; eye shielding; eye relapse; CNS relapse; cataract Total body irradiation (TBI) is an important part of the conditioning for bone marrow transplantation (BMT) for many hematological disorders in children and adults.
Summary:
This is a retrospective analysis of 188 children who underwent total body irradiation (TBI) in one or two fractions before bone marrow transplantation (BMT) for a hematological disorder. While 139 children had eye shielding during TBI to decrease cataract formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of relapse in the eyes or in the CNS after shielding of the eyes. The probability and severity of cataract formation with and without shielding were also evaluated. None of the 49 children without shielding had a relapse in their eyes or in the CNS after BMT. Of the children with shielding, none had a relapse in the eyes but two of the 139 (1.4%) had a CNS relapse. The incidence of cataracts without shielding was 90% (19 of 21 evaluable patients), while with shielding it was 31% (20 of 64). Severe cataracts were present in eight of 21 (38%) patients without and two of 64 (3%) patients with shielding. The probability of staying cataract free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a cataract without shielding vs shielding was three (95% CI ¼ 1.5; 5.9). It appears that the incidence of relapse in the eyes and CNS is not increased when the eyes are shielded during TBI. Shielding increased the latency time of cataract formation and decreased the severity of cataracts. Bone Marrow Transplantation (2003) 31, 1151-1156. doi:10.1038/sj.bmt.1704076 Keywords: TBI; eye shielding; eye relapse; CNS relapse; cataract Total body irradiation (TBI) is an important part of the conditioning for bone marrow transplantation (BMT) for many hematological disorders in children and adults. [1] [2] [3] Cataract formation is a known side effect of TBI. [4] [5] [6] [7] After single-dose TBI the probability of developing a cataract is reported to be 70-100%. [6] [7] [8] [9] [10] [11] [12] In more than 50% of these patients visual impairment is severe and cataract surgery may be necessary. 6, 9 An effective way of decreasing the risk of severe cataracts is to lower the radiation dose on the eye lenses by shielding the eyes. We applied this technique successfully to children who had TBI before BMT in Leiden and Utrecht. Shielding of the eyes, however, is controversial as the eyes (just as the CNS) are considered to be extramedullary sanctuaries. 13 We evaluated the data of all children who had a BMT with TBI as part of the conditioning in Leiden and Utrecht with the aim of investigating relapse incidence in the eyes after eye shielding during TBI. As the blocks used for shielding cause tiny but tall cylindrical areas of decreased dose intensity to the brain, we also evaluated the incidence of relapse in the CNS. Furthermore, we evaluated the effect of eye shielding on cataract formation.
Methods

Study design
We evaluated retrospectively the risk of relapse in the eyes and CNS after shielding the eyes during TBI. Participants included all children who had TBI as part of the conditioning regimen for BMT from 1980 until 1999, in the Department of Pediatric Hematology of the University Medical Centers of Leiden and Utrecht in the Netherlands. As a second end point, we also determined the incidence and severity of cataract formation and the probability of remaining cataract-free with and without eye shielding.
Patients
A total of 188 children underwent allogeneic (n ¼ 181) or autologous (n ¼ 7) BMT with TBI as part of their conditioning regimen. All children were transplanted for a hematological disorder (Table 1) . Before BMT, the majority of the patients was treated with systemic chemotherapy and elective CNS therapy following the appropriate protocols of the Dutch Childhood Leukemia Study Group. Within the framework of these protocols, 18 of the children received irradiation to the CNS before BMT as prophylaxis (n ¼ 8), or therapy because of CNS involvement at diagnosis or relapse (n ¼ 7) or both (n ¼ 3). The conditioning regimens for BMT in Leiden and Utrecht were identical. Conditioning always consisted of chemotherapy plus TBI. In 139 of the 188 children transplanted after 1988, shielding of the eyes was applied during TBI; in 49 children the eyes were not shielded. Table 1 shows patient characteristics (age, gender, diagnosis, type of BMT, previous cranial irradiation, and eye or CNS involvement before BMT). Table 2 gives characteristics of the TBI (total dose, dose rate, fraction size and age in relation to TBI). Table 3 gives characteristics of the disease with respect to eye or CNS involvement (infiltration of the eyes or CNS at primary diagnosis, number and place of CNS/eye relapses) before BMT.
Preparative regimen and GVHD prevention
Besides use of TBI, the preparative regimen for AML, CML and MDS consisted either of cyclophosphamide alone (60 mg/kg i.v.) on two consecutive days (n ¼ 38), or the combination of cyclophosphamide plus Ara-C (2000 mg/m 2 /day i.v.) on two consecutive days (n ¼ 48). For patients suffering from ALL or non-Hodgkin's lymphoma (NHL) the conditioning consisted either of cyclophosphamide alone (n ¼ 40) or of cyclophosphamide plus VP16 (350 mg/kg/day i.v.) on two consecutive days (n ¼ 51). In total, 11 children (ALL ¼ 6, AML ¼ 3, CML ¼ 1 and MDS ¼ 1) had TBI in combination with other chemotherapy. TBI was applied after 1 day rest and given in one single fraction, or in two fractions on two consecutive days (Table 2) . Six children, aged less than 2 years and grafted before 1990, were treated with a single fraction of 5 Gy (MDS ¼ 1 and AML ¼ 3) or 6 Gy TBI (ALL ¼ 2). After 1990 no TBI was applied when children were younger than 2 years old. GVHD prophylaxis consisted of cyclosporin-A 7 methotrexate. No T-cell depletion of the bone marrow was performed, except for patients who were recipients of a matched unrelated donor graft. When patients developed GVHD methylprednisolone was given (2 mg/kg/day) i.v. until the disease subsided. Subsequently it was continued orally, tapering the dose to zero if possible. When GVHD was progressive the dose of (methyl)prednisolone was raised temporarily and sometimes combined with other forms of immune-suppressive therapy. Prednisolone therapy was given to 34 patients for acute or chronic GVHD; 25 of these 34 patients were treated with steroids for 3 months or more after BMT. The relatively small number of children who needed long-term steroids for GVHD was caused by the fact that in Leiden children received complete intestinal decontamination in strict protective isolation for about 30 days post-BMT, resulting in a reduced number of patients suffering from GVHD. a Of these eight patients, three patients who had therapeutical cranial irradiation of 24 Gy also had prophylactical cranial irradiation before BMT of o18 Gy. Prev.=previous. (Table 2) . During the study period, the fractionation regimen for children older than 10 years was changed from one to two fractions. In both Leiden and Utrecht patients were irradiated in a lying position anteriorly and posteriorly. When eye protections were applied, they consisted of + 3 cm leaden blocks (Leiden) or + 3 cm stainless-steel cylinders (Utrecht) placed in the anterior field only. The dose reduction achieved by blocking the eyes was 55% of the total TBI dose, calculated midplane at the level of the umbilicus of the patient in Leiden and 58% of the total TBI dose in Utrecht.
Assessment of eye-and CNS involvement and cataract assessment
CNS involvement was defined as the presence of blast cells in the cerebrospinal fluid or the presence of cranial nerve palsies. Lumbar puncture was performed routinely at diagnosis, when a systemic relapse was diagnosed, or because of a clinically suspected CNS relapse. Eye involvement was determined by an ophthalmologist by physical examination of the eye (fundoscopy), combined, if indicated, with echography, CT-scanning and aspiration cytology when possible. Sometimes eye localizations were diagnosed on clinical appearance at fundoscopy. 14 Fundoscopy was only performed when CNS involvement was diagnosed or when eye involvement was suspected. Eight patients showed involvement of the CNS (n ¼ 6) or eyes (n ¼ 2) at diagnosis. In all, 18 patients experienced a relapse in the CNS as the site of first relapse prior to BMT and only one patient had a relapse in an eye as the site of first relapse. Of the 18 patients with a CNS relapse, two had a second relapse before BMT (Table 3) . Examination of the eyes for cataract development was performed during yearly routine slit-lamp examination in the beginning of the follow-up period of each patient. In later years, examination by slit-lamp occurred in nearly all patients at more irregular intervals. To study the effect of eye shielding on cataract development, children were only included when they had at least one examination of the lenses, performed 2 years or more after BMT. The diagnosis 'severe cataract' was used when corrective surgery was performed, or when the need for cataract surgery had been clearly established but surgery had not yet been performed.
Statistical evaluation
SPSS version 10.0 was used for statistical evaluation of the data. Kaplan-Meier product-limit estimates were used to evaluate cataract-free duration. For evaluation of the cataract-free duration only patients were included who had fundoscopy 2 years or more after BMT. Patients who died from a late relapse or other causes without having a cataract, who were lost from (ophthalmic) follow-up without having a cataract or were cataract-free on January 2001, were considered censored.
Results
Of the 188 patients who had a BMT, 66 experienced a relapse of their disease after BMT. Only the first relapse is considered. The site of the first relapse after BMT is shown in Table 4 . Of the 49 patients who had no eye shielding during TBI, none had a relapse in their eyes or the CNS. From the 139 patients who had eye shielding none had a relapse in the eyes while two had a CNS relapse; one a solitary CNS relapse and the other a combined bone marrow and CNS relapse. The patient who had a solitary CNS relapse suffered from ALL and had also a CNS relapse before BMT. The patient with a combined bone marrow and CNS relapse suffered from AML and had no relapse before BMT and no CNS involvement at diagnosis.
A total of 129 children survived for 2 years or more after BMT. They were therefore eligible for cataract assessment. Of these children, 44 were not evaluable as they had had no ophthalmic follow-up 2 years or more after BMT. In all, 85 children were evaluable of whom 64 had eye shielding during TBI and 21 had none. All but two of the 21 children without shielding of the eyes developed a cataract (90%). In six of these 19 cases cataract surgery was performed and, in two cases, cataract surgery was judged to be necessary, but had not yet been performed, giving an incidence of 38% 
a one patient relapsed in the CNS at first relapse and in the eye at second relapse. b one of the 13 patients relapsed in the CNS at first relapse and again at second relapse.
Eye shielding during TBI for BMT in children ML van Kempen-Harteveld et al severe cataract in patients without eye shielding. Of the 64 children who had shielding, 44 had no cataract at the last follow-up visit. In 20 patients a cataract developed and two underwent cataract surgery, indicating severe cataract in only 3% of the 64 children (follow-up 24-118 months). The probability of remaining cataract free was 0.33 (s.e. ¼ 0.10) at 5 years follow-up for the children without lens shielding, while at 8 years follow-up it was 0.24 (s.e. ¼ 0.09). For children with shielding of the eyes during the TBI the probability of remaining cataract free was 0.77 (s.e. ¼ 0.06) at 5 years and 0.53 (s.e. ¼ 0.10) at 8 years after BMT (Figure 1 ). Longer follow-up data, concerning the probability of remaining cataract-free, cannot be given as ophthalmic follow-up was irregular after 96 months. The influence of previous cranial irradiation on the incidence and severity of cataract formation without and with shielding could not be assessed, as nine of the children who had cranial irradiation prior to BMT (n ¼ 18) did not survive for 2 years (n ¼ 7) or did not have an examination of the eyes 2 years or more after BMT (n ¼ 2).
The influence of steroid therapy for GVHD (n ¼ 34) on the probability of staying cataract free was assessed for the children without and with eye shielding. However, the number of evaluable patients who were treated with steroids (24 of the 34 patients, of whom only 19 were treated with steroids for 3 months or more) appeared to be too small to draw any conclusions.
The relative risk (RR) of developing a cataract for patients without eye shielding was three times the risk of patients with shielding (95% CI 1.5; 5.9) (P ¼ 0.002); when patients treated with steroid therapy were excluded, the RR for patients without shielding was 2.9 (95% CI 1.4; 5.9) (P ¼ 0.003).
Discussion
When TBI is used as part of the conditioning regimen for BMT, and especially single-dose TBI, severe cataract needing cataract surgery is observed in a high percentage of patients. 6, 7, 9 This was also confirmed in the present study. Total dose, fractionation regimen and dose rate of the TBI are important factors influencing cataract formation and its severity. 2, 6, 10, 12, [15] [16] [17] Steroid treatment is known to induce cataracts in its own right [18] [19] [20] and can play an additional and synergistic role in cataract formation after BMT. [6] [7] [8] 12, 16 Age and cranial irradiation are mentioned as well by some authors as factors that might influence the formation of cataract. 12, 21 In our centers, lens shielding during TBI was used in children to decrease the incidence and severity of cataract after BMT. By lens shielding, using the technique as done in most centers (irradiation anteriorly and posteriorly) and applying shielding in the anterior field, the dose on the eye lens can be lowered to about 55-60% of the total TBI dose. The theoretical drawback of eye shielding is, however, that by lowering the dose on the eyes, residual leukemic cells might be able to survive. This may happen not only in the eyes, but a part of the CNS also has to be regarded as at risk. The fact is that the blocks used for shielding in the anterior field cause tiny but tall areas of decreased dose intensity to the brain. Eye shielding, therefore, is controversial.
Influence of eye shielding on relapse rate in eyes and CNS CNS relapses are reported to precede a systemic relapse and to worsen prognosis. 13, [22] [23] [24] [25] Relapse in eyes and CNS after BMT, however, appeared to be rare compared to the incidence of relapse in eyes and CNS after conventional treatment without the use of BMT. 26 Since cataract is a very disagreeable late complication in children and young adults, we decided to use eye shielding during TBI to prevent severe cataracts. In the present retrospective study, evaluating the data of all children treated until 1999, no relapses occurred in eyes or CNS of the children who had no eye shielding during the TBI (n ¼ 49). In the children who had lens shielding (n ¼ 139) no relapses were observed in the eyes; in the CNS, a relapse occurred in two out of the 139 patients. The CNS relapse percentage after BMT and TBI with eye shielding can thus be considered as very low: 1.4% (1.7% when only patients with acute leukemia are considered). In the literature an incidence of CNS relapse after BMT of 3.3-8.7% for ALL and of 0.2-1.4% for AML Table 4 Site of first relapse after BMT AML  19  1  20  ALL  1  29  3  3  36  NHL  1  1  2  CML  2  2  MDS  5 is reported (in patients who had TBI without eye shielding). [27] [28] [29] [30] Little is published about the incidence of CNS relapses after BMT in patients suffering from CML, NHL and MDS.
Disease Eye CNS BM BM+CNS Elsewhere BM+elsewhere Total
There are some reports in the literature about an increased risk in the CNS, after BMT in patients suffering from acute leukemia who had a previous history of CNS involvement. 27, 28 Singhal et al, 29 however, found no evidence of an increased risk of CNS involvement at presentation of the disease in 487 patients grafted for acute leukemia in first remission. In their series, only a few patients (n ¼ 11) had CNS involvement at presentation. In our study, 27 (13 without and 14 with eye shielding) out of 188 patients had eye/CNS involvement at presentation or at relapse prior to BMT. Despite the lower radiation dose to the eyes and part of the brain during the TBI, because of shielding in 139 of the patients, only two developed a relapse in the CNS. One of these two had CNS involvement at relapse before BMT. After BMT none of the patients had an ocular relapse. As patients with eye involvement represent usually only a very small percentage, there are few or no publications about the risk factors for developing a recurrence in the eyes after BMT. From our data, no definite conclusions can be drawn with respect to the probability of an increased risk of CNS or eye involvement after BMT in patients with CNS/eye involvement, because of the small number of relapses. It seems, however, to be the best policy not to shield the eyes of patients with a history of CNS or eye involvement prior to BMT.
Influence of eye shielding on cataract formation
A cataract developed in 90% of the children without lens shielding and 38% of them had a severe cataract. Of the children with shielding only 31% developed a cataract and 3% needed cataract surgery. The probability of staying cataract-free when eye shielding was used during TBI was significantly increased (Figure 1) . The RR of patients without shielding the eyes compared to patients with shielding was three. No effect of steroid treatment could be found, because of the small number of evaluable patients who needed long-term steroid treatment for GVHD (n ¼ 19). Cataracts appear to develop after a significantly longer latency time with shielding, but eventually they appear in a considerable proportion of patients. The major benefit from eye shielding, however, seems to be reduced severity of the cataracts as reflected by the reduced need for cataract surgery.
As cataract formation is described even after low radiation doses, 15 it is probably impossible to avoid cataracts completely after TBI. Also, after fractionated TBI (multiple fractions), which similar to eye shielding reduces the biological effectiveness of the TBI on the lens, cataracts will still develop. 6, 10, 12, 16, 17, 31 However, when the biological effectiveness of TBI is decreased, cataracts are known to develop after a longer latency period. 6, 16 In earlier studies 6, 7 it was found that cataracts developing late in the follow-up period, progress slowly and stabilize at a lower grade, giving minimal visual impairment. 9 The fact that shielding is probably safe for children treated with single-dose TBI or TBI in two fractions does not necessarily mean that shielding can also be applied safely during fractionated TBI using multiple fractions. The biological effectiveness of fractionated TBI on the eye lens varies according to fraction size and total dose. Its effectiveness, however, on the leukemic cells varies too, although probably to a lesser extent. 16 Shielding the eye lens during fractionated TBI could therefore theoretically have a different effect on the incidence of eye or CNS relapse compared to shielding during single-dose TBI.
Conclusion and recommendations
Shielding of the eye lens during TBI for BMT in one or two fractions, to prevent cataract formation or diminish its severity, does not seem to lead to an increased incidence of relapse in the eyes or the CNS after BMT. The probability of developing a severe cataract is markedly reduced after TBI with eye shielding.
Every patient in whom the eyes are planned to be shielded during TBI should have fundoscopy before starting the BMT procedure, to exclude disease infiltrates in the eyes. In patients with eye or CNS involvement prior to BMT no eye shielding should be used.
